Pirfenidone Capsule
Product Images NDC 59651-244

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 59651-244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Pirfenidone Fig1)

A cumulative distribution graph showing patients' change in percent predicted FVC from baseline to week 52 in a study comparing Pirfenidone (n=278) and placebo (n=277). The x-axis represents absolute change in %FVC from -30% to 10%, with vertical dashed lines at 0% and -10%. The y-axis shows the percentage of patients from 0% to 100%. Two curves depict the distribution for Pirfenidone and placebo groups, indicating differences in lung function change over time.*

FDA Label Image

Package Label.principal Display Panel (Maintenance Carton Pack)

Packaging label for Pirfenidone Capsules, USP 267 mg, an oral capsule medication by Aurobindo Pharma Limited. The carton contains 4 weekly packs totaling 252 capsules, with each weekly pack containing 63 capsules. The label warns to keep out of reach of children and notes blister cards are not child resistant. Distributed by Aurobindo Pharma USA, Inc.*

FDA Label Image

Figure2 (Pirfenidone Fig2)

A line graph titled 'Mean Change from Baseline in Forced Vital Capacity (Study 1)' comparing Pirfenidone and placebo groups over 52 weeks. The Y-axis shows mean change in forced vital capacity (mL), with values from 0 to -500. The X-axis shows weeks (0, 13, 26, 39, 52). Pirfenidone group data (n=278) is depicted with a solid line, showing less decline over time compared to the placebo group (n=277), shown with a dashed line illustrating a steeper decline.*

FDA Label Image

Figure3 (Pirfenidone Fig3)

Kaplan-Meier survival curve showing estimates of all-cause mortality over time in weeks for patients receiving Pirfenidone versus placebo. The graph presents percentage of patients alive on the vertical axis and time up to approximately 120 weeks on the horizontal axis. It includes patient numbers at risk at various time points and hazard ratio with confidence interval comparing Pirfenidone to placebo.*

FDA Label Image

Table Figue 4 (Pirfenidone Fig4)

A dosing schedule table for Pirfenidone Capsules 267 mg showing the number of capsules to be taken morning, afternoon, and evening across three time periods: Days 1 to 7 (1 capsule each time, total 3 daily), Days 8 to 14 (2 capsules each time, total 6 daily), and Days 15 onward (3 capsules each time, total 9 daily).*

FDA Label Image

Package Label.principal Display Panel (267 mg (270 Capsules Container Label))

Label for Pirfenidone Capsules USP 267 mg by Aurobindo Pharma Limited. The label states each capsule contains 267 mg Pirfenidone, with a package size of 270 capsules. It includes storage instructions for controlled room temperature and distributor information for Aurobindo Pharma USA, Inc. Barcodes and NDC 59651-244-27 are visible.*

FDA Label Image

Package Label.principal Display Panel (267 mg (270 Capsules Container Carton Label))

Packaging label for Pirfenidone Capsules, USP 267 mg by Aurobindo Pharma Limited. The label shows the product strength of 267 mg per capsule, total count of 270 capsules, and is marked Rx only. It includes storage instructions and distributor information for Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label.principal Display Panel (14-Day Titration Wallet Pack)

Pirfenidone Capsules USP 267 mg oral capsules in a 14-day titration pack containing 63 capsules, distributed by Aurobindo Pharma USA, Inc. The packaging shows blister cards labeled with dosing schedules for Week 1 and Week 2, with capsules arranged for morning, noon, and PM doses. The label includes storage instructions and manufacturer details.*

FDA Label Image

Package Label.principal Display Panel (14-Day Titration Carton Pack)

Packaging label for Pirfenidone Capsules USP 267 mg by Aurobindo Pharma Limited. The label indicates a 14-day titration pack containing 63 capsules with specific dosing instructions for weeks 1 and 2. The label includes storage conditions, distributor information, and warnings to keep out of reach of children. The product NDC 59651-244-42 is visible along with the Aurobindo logo.*

FDA Label Image

Package Label.principal Display Panel (Maintenance Wallet Pack)

Pirfenidone Capsules, USP 267 mg oral capsules in a weekly blister pack with 63 capsules total. The label includes storage instructions, manufacturer details for Aurobindo Pharma USA, Inc., and safety warnings about keeping out of reach of children. The image shows the front and back of the blister card packaging and dosage blister layout.*

FDA Label Image

Structure (Pirfenidone Str)

Chemical structure diagram of the active ingredient pirfenidone, showing its molecular arrangement with two benzene rings, one containing a methyl group and a carbonyl group attached to a nitrogen atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.